Hair Repigmentation With Anti-PD-1 and Anti-PD-L1 Immunotherapy: A Novel Hypothesis

Guillaume Manson, Aurélien Marabelle, Roch Houot

► To cite this version:

Guillaume Manson, Aurélien Marabelle, Roch Houot. Hair Repigmentation With Anti-PD-1 and Anti-PD-L1 Immunotherapy: A Novel Hypothesis. Journal of the American Medical Association, 2018, 154 (1), pp.113. 10.1001/jamadermatol.2017.4421 . hal-01699247

HAL Id: hal-01699247

<https://hal-univ-rennes1.archives-ouvertes.fr/hal-01699247>

Submitted on 28 Feb 2018

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Hair Repigmentation With Anti-PD-1 and Anti-PD-L1 Immunotherapy: A Novel Hypothesis

To the Editor

The article by Rivera et al¹ is the first report of a previously undescribed side effect of checkpoint inhibitors: hair repigmentation (HR). In this significant case series of 14 patients, all patients received an anti-programmed cell death 1 (PD-1) and anti-programmed cell death 1 ligand 1 (PD-L1) antibody for the treatment of a lung cancer.

We report an additional case illustrating that HR following PD-1 blockade is not limited to patients with lung cancer. A man in his 70s was diagnosed with Hodgkin lymphoma. Two years after treatment with chemotherapy, he experienced a re-lapse and was also diagnosed with metastatic colorectal cancer associated with microsatellite instability (CRC-MSI). Both cancers were treated in parallel but progressed within 3 years to involve the liver, lungs, spleen, and lymph nodes. Given the high sensitivity of Hodgkin lymphomas and CRC-MSI to anti-PD-1 antibodies, it was decided to treat the patient with nivolumab (3 mg/kg every 2 weeks).² The patient experienced a mixed response, with tumor regression at most tumor sites except for a liver metastasis, which was treated with local radiotherapy. The patient remained on nivolumab treatment for a year with acceptable toxic effects (grade 2 fatigue, grade 3 hepatitis, grade 2 hypothyroidism). One month after nivolumab treatment initiation, the patient reported HR of his whole body although he had harbored white hair for the last 25 years.

Hair and skin pigmentation is linked to immunity.³ As mentioned by Rivera et al,¹ other drugs can induce HR. Interestingly, most of them have immunomodulatory properties. It is also striking to notice that 14 of the 15 reported cases (including ours) are men. Although some biases may partly explain this sex imbalance (increased incidence of lung cancer in men, underdiagnosis of HR in women owing to hair dye), we make the hypothesis that these observations might highlight a patho-physiological substrate. Indeed, many immune genes are X-linked, some of which are involved in pigmentation disorders

(eg, *IKBKG*, *POLA1*).⁴ One of them, *FOXP3*, the critical driver of regulatory T cells (T-regs), is of peculiar interest because of increasing evidence regarding the role of T-regs in hair biology.⁵ Thus, immune modulation induced by PD-1/PD-L1 antibodies in patients with an X-linked gene polymorphism (eg, affecting T-regs) may explain both HR and the increased anti-tumor efficacy observed in almost all of these patients. Further studies are warranted to assess this hypothesis.

Guillaume Manson
Aurélien Marabelle, MD, PhD
Roch Houot, MD, PhD

Conflict of Interest Disclosure: None reported.

Author Affiliations: Department of Hematology, CHU Rennes, Rennes, France (Manson, Houot); Gustave Roussy, Université Paris-Saclay, Département d'Innovation Thérapeutique et d'Essais Précoces, Villejuif, F-94805, France (Marabelle); INSERM U1015, Gustave Roussy, Villejuif, France (Marabelle); INSERM, U1236, Rennes, France (Houot).

Corresponding Author: Roch Houot, MD, PhD, Department of Hematology, CHU Rennes, 2 rue Henri Le Guilloux, 35033 Rennes Cedex 9, France (roch.houot@chu-rennes.fr).

Additional Contributions: We are indebted to Caroline Robert, MD, PhD, Stéphane Champiat, MD, Jean-Pierre Armand, MD, and Jean-Marie Michot, MD, for sharing their expertise on this case. They received no compensation for their contributions.

1. Rivera N, Boada A, Bielsa MI, et al. Hair repigmentation during immunotherapy treatment with anti-programmed cell death 1 and anti-programmed cell death ligand 1 agent for lung cancer [published online July 12, 2017]. *JAMA Dermatol*. doi:10.1001/jamadermatol.2017.2106
2. Marabelle A, Routy B, Michels J, Kroemer G, Zitvogel L. Prime time for immune-checkpoint targeted therapy at ASCO 2015. *Oncoimmunology*. 2015;5 (3):e1068494.
3. Dwivedi M, Kemp EH, Laddha NC, Mansuri MS, Weetman AP, Begum R. Regulatory T cells in vitiligo: implications for pathogenesis and therapeutics. *Autoimmun Rev*. 2015;14(1):49-56.
4. Libert C, Dejager L, Pinheiro I. The X chromosome in immune functions: when a chromosome makes the difference. *Nat Rev Immunol*. 2010;10(8):594-604
5. Ali N, Zirik B, Rodriguez RS, et al. Regulatory T cells in skin facilitate epithelial stem cell differentiation. *Cell*. 2017;169(6):1119-1129.e11.